Novel drugs targeting Toll-like receptors for antiviral therapy.
Novel drugs targeting Toll-like receptors for antiviral therapy.
复制标题
DOI：
10.2217/fvl.14.70
复制
发表时间：
2014-09
期刊：
影响因子：
3.1
通讯作者：
Blanco JC
中科院分区：
文献类型：
--
作者：
Patel MC;Shirey KA;Pletneva LM;Boukhvalova MS;Garzino-Demo A;Vogel SN;Blanco JC
Toll样受体（TLR）是宿主先天免疫系统的哨兵受体，可识别入侵微生物（包括病毒）的保守“病原体相关分子模式”。TLR的激活建立抗病毒先天免疫应答，并协调持久的适应性免疫的发展，以控制病毒的发病机制。然而，微生物对宿主组织的损伤可能会释放出“与炎症相关的分子模式”，这些分子模式也会激活TLR，导致过度的炎症反应，最终导致组织损伤。因此，TLR已被证明是作为用于治疗导致炎性损伤的病毒感染的治疗剂或作为佐剂以增强疫苗功效的有前景的靶标。在这里，我们探讨了TLR生物学的最新进展，重点是靶向TLR（激动剂和拮抗剂）的抗病毒治疗的新型药物。
Toll-like receptors (TLRs) are sentinel receptors of the host innate immune system that recognize conserved ‘pathogen-associated molecular patterns’ of invading microbes, including viruses. The activation of TLRs establishes antiviral innate immune responses and coordinates the development of long-lasting adaptive immunity in order to control viral pathogenesis. However, microbe-induced damage to host tissues may release ‘danger-associated molecular patterns’ that also activate TLRs, leading to an overexuberant inflammatory response and, ultimately, to tissue damage. Thus, TLRs have proven to be promising targets as therapeutics for the treatment of viral infections that result in inflammatory damage or as adjuvants in order to enhance the efficacy of vaccines. Here, we explore recent advances in TLR biology with a focus on novel drugs that target TLRs (agonists and antagonists) for antiviral therapy.